Last reviewed · How we verify
XR-BUP
At a glance
| Generic name | XR-BUP |
|---|---|
| Also known as | extended-release buprenorphine, CAM2038, Brixadi |
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Extended-release Buprenorphine as a Novel Low-dose Induction Strategy (PHASE2)
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
- Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial (PHASE4)
- Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder (PHASE3)
- Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR) (PHASE3)
- Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (PHASE2)
- EXHIT ENTRE Comparative Effectiveness Trial (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XR-BUP CI brief — competitive landscape report
- XR-BUP updates RSS · CI watch RSS
- NYU Langone Health portfolio CI